Asthma  >>  Flutiform (fluticasone/formoterol)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
NCT02388373 / 2013-005365-39: A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down

Completed
4
225
Europe
Fluticasone 250/formoterol 10, Flutiform 250, Fluticasone 250/salmeterol 25, Seretide 250 Evohaler, Fluticasone 125/formoterol 5, Flutiform 125
Research in Real-Life Ltd, Napp Pharmaceuticals Limited
Asthma
02/16
03/16
RECONFFIRM, NCT02491970: Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

Terminated
4
15
NA
Fluticasone/Formoterol, Flutiform, Fluticasone/Salmeterol, Seretide
Mundipharma Korea Ltd
Asthma
04/17
05/17
2015-000172-98: An Open Label Oxygen Enhanced Imaging Biomarker Study in Moderate to Severe Asthma.

Completed
4
17
Europe
flutiform, Inhalation vapour, flutiform
The University of Leicester, Napp Pharmaceutical Limited
Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2019-003864-27: Effect of inhalation formulation on uncontrolled asthma

Not yet recruiting
4
70
Europe
Flutiform K-haler, Relvar Ellipta, Inhalation solution, Inhalation powder, Flutiform K-haler, Relvar Ellipta
HUS / Mika Mäkelä, Mika Mäkelä
Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
NCT04271839 / 2020-000302-28: Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients

Withdrawn
4
208
NA
fluticasone/formoterol k-haler (medium strength), No other interventions, Standard of care (ICs/LABA high strength)
Mundipharma Pharmaceuticals S.L., Alpha Bioresearch S.L., Dynamic Solutions
Persistent Asthma
05/21
05/21

Download Options